Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis

被引：8
|
作者：
Doshi, Bhavya S. [1 ,2 ]
Witmer, Char M. [1 ,2 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3501 Civ Ctr Blvd,CTRB 5024, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA
来源：
HAEMOPHILIA | 2021年 / 27卷 / 04期
关键词：
emicizumab; haemophilia A; immune tolerance; inhibitor; recurrence; IMMUNE TOLERANCE;
D O I：
10.1111/hae.14311
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E551 / E553
页数：3
相关论文
共 50 条
  • [41] Secondary prophylaxis in an adult patient with severe haemophilia A Factor VIII consumption and effectiveness
    Schlenkrich, S.
    Schubert, C.
    HAMOSTASEOLOGIE, 2013, 33 (03): : 241 - 244
  • [42] EMICIZUMAB THERAPY LEADING TO RESOLUTION OF LIFE-THREATENING HAEMATURIA AT THE PATIENT WITH MILD HAEMOPHILIA A AND HIGH TITRE INHIBITORS
    Rener, K.
    Doma, S. Anzej
    Zupan, I. Preloznik
    Fink, M.
    HAEMOPHILIA, 2020, 26 : 90 - 90
  • [43] Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high-titre inhibitor (vol 4, pg 762, 1998)
    Montoro, JB
    Altisent, C
    Pico, M
    Cabañas, MJ
    Vila, M
    Puig, LL
    HAEMOPHILIA, 1999, 5 (05) : 371 - 371
  • [44] Recombinant FVIIa in the management of Port-a-Cath access in a boy with severe hemophilia a and high-titre inhibitor: was it prophylaxis?
    Heine, S., I
    Krenn, T.
    Graf, N.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1138 - 1139
  • [45] Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates
    Zanon, E
    Zerbinati, P
    Girolami, B
    Bertomoro, A
    Girolami, A
    BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (03) : 117 - 120
  • [46] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
    Pipe, S. W.
    Collins, P.
    Dhalluin, C.
    Kenet, G.
    Schmitt, C.
    Buri, M.
    Jimenez-Yuste, V.
    Peyvandi, F.
    Young, G.
    Oldenburg, J.
    Mancuso, M. E.
    Kavakli, K.
    Kiialainen, A.
    Niggli, M.
    Chang, T.
    Lehle, M.
    Fijnvandraat, K.
    HAEMOPHILIA, 2024, 30 : 24 - 25
  • [47] COST-MINIMISATION ANALYSIS OF RECOMBINANT FACTOR VIII FC FUSION PROTEIN VERSUS EMICIZUMAB FOR HAEMOPHILIA A PROPHYLAXIS IN EUROPE
    Hakimi, Z.
    Nazir, J.
    Pochopien, M.
    Aballea, S.
    Skrzeczek, A.
    VALUE IN HEALTH, 2020, 23 : S743 - S743
  • [48] Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis"
    Messori, Andrea
    Peyvandi, Flora
    Trippolit, Sabrina
    Palla, Roberta
    Rosendaal, Frits R.
    Mannucci, Pier Mannuccio
    BLOOD TRANSFUSION, 2019, 17 (01) : 86 - 86
  • [49] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [50] Low factor VIII recovery in haemophilia A patients without inhibitor titre is not due to the presence of anti-factor VIII antibodies undetectable by the Bethesda assay
    Mondorf, W
    Klinge, J
    Luban, NLC
    Bray, G
    Saenko, E
    Scandella, D
    HAEMOPHILIA, 2001, 7 (01) : 13 - 19
12345